BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics
BIORCHESTRA is an emerging biotech in Korea. Its lead program, BMD-001, shows disease-modifying potential for treatment of neurodegenerative diseases by targeting a specific miRNA. BIORCHESTRA has been selected as the first awardee of J&J’s Innovation Quick Fire Challenge on Neuroscience in June, 2021. Destum Partners, a U.S.-based advisory and consulting firm for the biopharmaceutical and life sciences industries, is BIORECHSTRA’s advisor. For more information, visit BIORCHESTRA’s website at http://biorchestra.com/.
SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng and SK life science’s website at www.SKLifeScienceInc.com
 miRNAs are a class of noncoding RNA that regulate post-transcriptional gene expression via translational repression. miRNAs are gaining attention as a novel target for diagnosis and treatment of various diseases. Front. Endocrinol., 03 August 2018. https://doi.org/10.3389/fendo.2018.00402
 Antisense oligonucleotides (ASO) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms. Rinaldi, C., Wood, M. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14, 9–21 (2018). https://doi.org/10.1038/nrneurol.2017.148